** Shares of drug developer Praxis Precision Medicines PRAX.O fall 39.2% to $39.51 premarket, set to open at an over eight-month low
** Co says an independent committee has recommended stopping its tremor drug trial, as it was unlikely to meet the main goal of the study; PRAX says it will continue the trial with changes to its analysis methods
** The experimental drug, ulixacaltamide, is being tested in the late-stage study to treat essential tremor, a condition that affects the nervous system and causes involuntary and rhythmic shaking
** Stock has risen 33.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.